Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs

  title={Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs},
  author={Matilde Manzoni and Manuela Rollini},
  journal={Applied Microbiology and Biotechnology},
  • M. Manzoni, M. Rollini
  • Published 14 February 2002
  • Biology, Chemistry
  • Applied Microbiology and Biotechnology
Abstract. Hypercholesterolemia is considered an important risk factor in coronary artery disease. Thus the possibility of controlling de novo synthesis of endogenous cholesterol, which is nearly two-thirds of total body cholesterol, represents an effective way of lowering plasma cholesterol levels. Statins, fungal secondary metabolites, selectively inhibit hydroxymethyl glutaryl-coenzyme A (HMG-CoA) reductase, the first enzyme in cholesterol biosynthesis. The mechanism involved in controlling… 
A review on lovastatin and its production
Lovastatin application part is in various field like management of hypercholesterolaemia, cholesterol lowering actions, reduce the prevalence of Alzheimer’s and renal disease etc.
Screening of different fungi for production of lovastatin
In the present study, seven wild fungi were screened for lovastatin production by bioassay method against C. albicans and N. crassa and the results showed that, Aspergillus terreus NCIM 657 produced the maximum lovastsatin in the screening work through submerged fermentation.
Simvastatin: Biological Production, Therapeutic Applications and Proposed Alternative Hypothesis for Biosynthesis
The present review deals with the structure, biosynthesis, pharmacological properties, therapeutic applications and alternative strategies for biological synthesis of simvastatin.
Single-step fermentative production of the cholesterol-lowering drug pravastatin via reprogramming of Penicillium chrysogenum
Reprogramming of the antibiotics-producing fungus Penicillium chrysogenum, with discovery and engineering of an enzyme involved in the hydroxylation of compactin, enables high level fermentation of the correct form of pravastatin to facilitate efficient industrial-scale statin drug production.
Microbial Production and Biomedical Applications of Lovastatin
The structure, biosynthesis, various modes of fermentation and applications of lovastatin, a potent hypercholesterolemic drug used for lowering blood cholesterol, are reviewed.
Exploitation of Aspergillus terreus for the Production of Natural Statins
The discovery of statins, along with strategies that have been applied to scale up their production by A. terreus strains are reviewed, which encompass many of the techniques available in industrial microbiology and include the optimization of media and fermentation conditions.
HMG-CoA Reductase Inhibitory Activity of Leaf-associated Fungi
It is very promising that a novel statin compound, or even a new class of substances with antihypercholesterolemic bioactivity may be discovered from these leaf-associated fungal isolates, which are prime candidates for downstream fractionation for the subsequent isolation and structureelucidation of the bioactive compound.
Molecular mechanisms of toxicity of simvastatin, widely used cholesterol-lowering drug. A review
Details about statins including their adverse effects in humans and animals, the effects of simvastatin on various intracellular and mitochondrial processes, and molecular mechanisms underlying simvastsatin cytotoxicity are discussed.


Discovery, biochemistry and biology of lovastatin.
  • A. Alberts
  • Biology, Chemistry
    The American journal of cardiology
  • 1988
Differential metabolism of statins: importance in drug-drug interactions
The pharmacokinetic properties of the statins and how they affect the use of these agents in clinical practice are described here.
Recent advances in the biosynthetic studies of lovastatin.
This review highlights early work done in the elucidation of lovastatin biosynthesis involving the use of labeled precursors and the incubation of putative intermediates with cell-free extracts from various fungal sources.
Monacolins J and L, new inhibitors of cholesterol biosynthesis produced by Monascus ruber.
The present communication describes the isolation, structure and some of the biological properties of two new compounds designated monacolins J and L, both of which have shown the potential in treating hypocholesterolemic disorders.
New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
Lovastatin (mevinolin, Mevacor), which is in the late stages of clinical development and has been administered to over 1000 subjects for up to 4 years, is the inhibitor on which the most information is available and is a very effective and usually well-tolerated lipid-lowering agent.
Structural Mechanism for Statin Inhibition of HMG-CoA Reductase
The structures of the catalytic portion of human HMGR complexed with six different statins are determined, which show several catalytically relevant residues are disordered in the enzyme-statin complexes.
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Production of statins by filamentous fungi
Several Monascus and Aspergillus strains were screened for statins production. Lovastatin, monacolin J, pravastatin and mevastatin were produced, with higher yields from the A. terreus strains than
A Quarter Century of Drug Treatment of Dyslipoproteinemia, With a Focus on the New HMG‐CoA Reductase Inhibitor Fluvastatin
The Lipoprotein and Coronary Atherosclerosis Study, a randomized, double‐blind trial of fluvastatin using quantitative coronary angiography to measure atherosclerotic plaque change and positron emission tomography to evaluate myocardial perfusion (myocardial flow reserve), illustrates the further exploration of lipoproteins and atherogenesis made possible by the availability of this new generation of cholesterol‐lowering agents.
Screening fungi for the production of an inhibitor of HMG CoA reductase: Production of mevinolin by the fungi of the genus Pleurotus
F fungi of the basidiomycetous genus Pleurotus, especially species P. ostreatus, P. saca and P. sapidus, are an as yet unknown but promising source of the hypocholesterolaemic agent.